Currently there are no proven treatments or vaccines for COVID-19 and care of the COVID patients is largely supportive involving treatment of symptoms such as fever with antipyretics, secondary bacterial chest infection with antibiotics and meticulous management of comorbid conditions. Several repurposed and new drugs have been investigated for treatment of COVID-19, however, none have been confirmed to be efficacious. These drugs include the antimalarials (chloroquine and hydroxychloroquine), antivirals such as remdesivir and favipiravir and antiretroviral combination therapies such lopinavir/ritonavir. There is emerging evidence to support the use of COVID convalescent plasma for the treatment of COVID-19. There is need to leverage the blood transfusion services in countries and this is beginning to happen on the continent.
Currently there are no proven treatments for COVID-19 and current standard therapy is
supportive care with oxygen supplementation and treatment of symptoms. While treatments are
being investigated in the Western world, it is likely that these data will take several
months to become available and if proven to be efficacious, access in most of the low-income
countries will be limited due to the high global demand and exorbitant costs.
In this study, the investigators aim to assess the safety and efficacy of use of CCP for
treatment of adults with COVID-19 in Uganda.
The investigators hypothesise that administration of CCP to patients with positive SARS-CoV-2
RT PCR leads to earlier time to viral clearance compared to the standard of care.
Objectives:
General objective The overall objective of this project is to assess the safety and efficacy
of COVID-19 convalescent plasma in the treatment of COVID-19 in Uganda.
Primary objective
1. To determine the efficacy of COVID-19 Convalescent Plasma, as measured by time to RT-PCR
negativity of COVID-19 patients treated with COVID-19 Convalescent Plasma.
Secondary objectives
1. To assess the safety of COVID-19 Convalescent Plasma in the treatment of COVID-19
patients in Uganda
2. To document the time to symptom decrease of patients with positive SARS-CoV-2 RT PCR
treated with CCP compared to those on standard of care
3. To assess the ability of CCP therapy to stop progression to severe/critical forms of
disease This study will be a prospective randomized two arm open label clinical trial.
Patients with confirmed COVID-19 who meet the study eligibility criteria will be
randomized to receive either CCP in addition to standard of care therapy or standard of
care therapy alone.
Biological: COVID Convalescent Plasma
Plasma collected from recovered COVID 19 individuals
Inclusion Criteria:
- Adults with documented laboratory RT PCR confirmed SAR-CoV-2 infection
- Patients able to provide informed consent. In the event that the patient cannot
provide consent e.g. they are severely sick, the next of kin or legal surrogate
decision make
Exclusion Criteria:
- Prior diagnosis of IgA deficiency
- Inability to return for post discharge follow up
Mulago Specialised Hospital
Kampala, Uganda